Prion protein (PrP) amyloidosis is a feature of Gerstmann-Straussler-S
cheinker disease (GSS) and prion protein cerebral amyloid angiopathy (
PrP-CAA). GSS and PrP-CAA are associated with point mutations of the p
rion protein gene (PRNP); there is a broad spectrum of clinical presen
tations and the main signs are ataxia, spastic paraparesis, extrapyram
idal signs and dementia. In GSS, parenchymal amyloid may be associated
with spongiform changes or neurofibrillary lesions; in PrP-CAA, vascu
lar amyloid is associated with neurofibrillary lesions. In the two dis
eases, a major component of the amyloid fibrils is a 7 kDa peptide, ap
proximately spanning residues 81-150 of PrP.